This funding call focuses on enhancing cell therapies through genomic techniques to overcome existing bottlenecks in the safe and efficient application of cell-based therapies. The aim is to advance the design of engineered cells, ensuring better delivery efficiency, safety, persistence, and therapeutic effects. The initiative seeks to address any disease, dysfunction, or health impairment by developing 'off-the-shelf' allogeneic cell-based therapies using human cells.

Key objectives include the integration of synthetic genetic circuits, the use of genomic editing tools, and collaboration with regulatory authorities for pre-clinical validation. The project will also consider sex differences, encourage SME participation, and foster collaborations with European research infrastructures. The use of CAD tools and demonstration in appropriate pre-clinical models is emphasized. Proposals should showcase the safety and therapeutic efficacy of engineered cells and aim to engage with clinical studies.

Opening: 22 May 2025

Deadline(s): 18 Sep 2025 (First Stage), 16 Apr 2026 (Second Stage)

Data provided by Kooperationsstelle Wissenschaft

This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.